HLA-iPSC#1
KAIMRCi002-A
General
Cell Line |
|
| hPSCreg name | KAIMRCi002-A |
| Cite as: | KAIMRCi002-A (RRID:CVCL_D0H0) |
| Alternative name(s) |
HLA-iPSC#1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
KAIMRCi002-B (HLA-iPSC#2) |
| Last update | 14th September 2023 |
| User feedback | |
Provider |
|
| Generator | King Abdullah International Medical Research Center (KAIMRC) |
| Owner | King Abdullah International Medical Research Center (KAIMRC) |
| Distributors | |
| Derivation country | Saudi Arabia |
External Databases |
|
| BioSamples | SAMEA113570217 |
| Cellosaurus | CVCL_D0H0 |
| Wikidata | Q123032791 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 25-29 |
| Ethnicity | Saudi |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Whole genome sequencing
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA114383884 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | King Abdullah International Medical Research Center |
| Approval number | RJ20/134/J |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
Committed, erythroid stem cells derived from myeloid stem cells. The progenitor cells develop in two phases: erythroid burst-forming units (bfu-e) followed by erythroid colony-forming units (cfu-e). Bfu-e differentiate into cfu-e on stimulation by erythropoietin, and then further differentiate into erythroblasts when stimulated by other factors.
|
| Age of donor (at collection) | 25-29 |
| Collected in | 2021 |
| Passage number reprogrammed | 1 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Files and images showing reprogramming vector expressed or silenced | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ Plus
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
|
|
||
| NANOG |
Yes |
|
|
|
||
| SOX2 |
Yes |
|
|
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| Brachyury or TBXT |
Yes |
Microbiology / Virus Screening |
|
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.